CompletedNCT00634348

A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Medication studyAges 18–70United States

The study in practice

Understand this study

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations: Anaheim and 40 more locationsSee all locations and recruitment
Study phase: Phase 4

Study clarity

Study start dateApril 2004

Recruitment status: Completed
Enrollment listed in the registry: 256
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: United States
Age range: From 18 Years to 70 Years
Official registry ID: NCT00634348
Official title: Show the full official title
A Four-Week Double Blind Multicenter Study Comparing The Efficacy And Safety Of Ziprasidone To Aripiprazole In Subjects With Schizophrenia Or Schizoaffective Disorder Needing Inpatient Care

Completed

Anaheim · Cerritos · Culver City

33 more locations

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole and Ziprasidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.